# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ronald Reagan (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML008-SYN
- Date: 2026-04-14
- Fictional facility: St. Posthumous Health Center
- Fictional author: Margaret Ellison, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Three-month post-fracture review with bone density testing and zoledronic acid. **S**

## History of present illness

Mr. Reagan returns three months after the repair of his right hip fracture. He now walks in the house and out to the garden with his walker and supervision, and enjoys sitting outside. His hip no longer hurts, even after walking, and he has had no falls. Home physical therapy continues twice a week. His caregivers give cholecalciferol every day and report no missed doses of it or of donepezil. The evening restlessness is mild and unchanged, and the evening routine still settles it. His appetite is good, and he has gained 1 kg. **S**

| Element | Detail |
|---|---|
| Interval change | Walking in the house and garden with a walker and supervision; no hip pain |
| Falls | None |
| Medicines | Donepezil and cholecalciferol taken daily; acetaminophen no longer needed |
| Behavior | Mild evening restlessness, unchanged |
| Function | Barthel Index 75, up from 55 at the first visit |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Appetite good; weight up 1 kg; no fever |
| Cardiovascular | Negative | No lightheadedness on standing or fainting |
| Gastrointestinal | Negative | No heartburn, nausea, or trouble swallowing |
| Musculoskeletal | Negative | No hip pain; no back pain |
| Neurological | Positive | Known memory loss, unchanged |
| Psychiatric | Positive | Mild evening restlessness; no low mood; GDS-15 score 3 |

6 systems reviewed. **S**

## Current medications

- Donepezil 10 mg oral tablet, one tablet by mouth daily in the morning **S**
- Cholecalciferol 50 mcg (2,000 units) oral tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 130/72 mmHg; pulse 64 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 77.5 kg; BMI 22.6 kg/m². All vital signs are synthetic.

Hemoglobin: 13.4 g/dL; Sodium: 138 mmol/L; Potassium: 4.4 mmol/L; Creatinine: 1.08 mg/dL; eGFR: 63 mL/min/1.73 m²; Glucose: 94 mg/dL; Calcium: 9.3 mg/dL; 25-hydroxyvitamin D: 36 ng/mL; Alkaline phosphatase: 112 U/L; Left total hip bone mineral density by DXA: 0.637 g/cm2 (low); Barthel Index: 75; GDS-15: 3. All results are synthetic.

## Change since baseline

- Hemoglobin: 11.1 g/dL (low) at baseline, 13.4 g/dL at this visit **S**
- Sodium: 137 mmol/L at baseline, 138 mmol/L at this visit **S**
- Potassium: 4.3 mmol/L at baseline, 4.4 mmol/L at this visit **S**
- Creatinine: 1.12 mg/dL at baseline, 1.08 mg/dL at this visit **S**
- eGFR: 61 mL/min/1.73 m² at baseline, 63 mL/min/1.73 m² at this visit **S**
- Glucose: 96 mg/dL at baseline, 94 mg/dL at this visit **S**
- Calcium: 9 mg/dL at baseline, 9.3 mg/dL at this visit **S**
- 25-hydroxyvitamin D: 16 ng/mL (low) at baseline, 36 ng/mL at this visit **S**
- Alkaline phosphatase: 134 U/L (high) at baseline, 112 U/L at this visit **S**
- Barthel Index: 55 at baseline, 75 at this visit **S**
- GDS-15: 4 at baseline, 3 at this visit **S**

## Immunizations given today

- Pneumococcal conjugate vaccine PCV20 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Alert, pleasant, and well groomed |
| Cardiovascular | Regular rhythm at 64 per minute; no edema; no fall in blood pressure on standing, without symptoms |
| Musculoskeletal | Right hip incision well healed; painless hip movement; no spinal tenderness; walks with the walker and supervision, steadier than at the last visit |
| Neurological | Oriented to person, not to date; no focal weakness |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Osteoporosis with right hip fragility fracture, healing** (M80.051D). The fracture is clinically healing. DXA today shows a left total hip T-score of -2.8 (0.637 g/cm²) and a lumbar spine T-score of -1.9. Calcium 9.3 mg/dL, eGFR 63, and creatinine clearance about 50 mL/min allow zoledronic acid. The raised PTH and alkaline phosphatase at the first visit fit the vitamin D deficiency; alkaline phosphatase is now normal at 112. **S**
   - Zoledronic acid 5 mg intravenously over at least 15 minutes today, after a glass of water; his caregivers will watch for flu-like aches over the next three days.
   - Continue cholecalciferol 2,000 units daily and calcium from food.
   - Stop scheduled acetaminophen, since he has no pain.
   - Calcium and kidney function before the second infusion in a year.
2. **Vitamin D deficiency, repleted** (E55.9). 25-hydroxyvitamin D 36 ng/mL, up from 16. **S**
   - Continue cholecalciferol; recheck yearly.
3. **Acute blood loss anemia after hip surgery, resolved** (D62). Hemoglobin 13.4 g/dL, up from 11.1. **S**
   - Recheck hemoglobin at six months.
4. **Dementia due to Alzheimer's disease, moderate (FAST stage 5)** (F02.B0). Stable by observation and his caregivers' account. GDS-15 score 3, below the threshold for depression. Heart rate 64 on donepezil. **S**
   - Continue donepezil and the evening routine.
   - POLST form completed today with the patient taking part as he was able, reflecting the goals of care discussed in February.
5. **History of falling** (Z91.81). No falls. Walking goal met with a Barthel Index of 75. **S**
   - Continue home physical therapy; Timed Up and Go when therapy ends.
6. **Immunization**. No pneumococcal vaccine on record. **S**
   - Pneumococcal conjugate vaccine PCV20 given today.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Serum calcium and kidney function before zoledronic acid | Before each intravenous dose | Completed today | Calcium 9.3 mg/dL; creatinine 1.08 mg/dL, eGFR 63, creatinine clearance about 50 mL/min, above the 35 mL/min limit |
| Laboratory | 25-hydroxyvitamin D and alkaline phosphatase after repletion | Repeat after repletion, then yearly | Completed today | Vitamin D 36 ng/mL, up from 16; alkaline phosphatase back to normal at 112 U/L |
| Laboratory | Hemoglobin | Follow-up of postoperative anemia | Completed today | 13.4 g/dL, up from 11.1 |
| Laboratory | Phosphorus and 24-hour urine calcium | Once, in the secondary-causes workup before treatment | Deferred | Not obtained before today's infusion, a deviation from the protocol. Serum calcium, PTH, and alkaline phosphatase point to vitamin D deficiency as the only secondary cause, so a missed cause that would change treatment is unlikely. Phosphorus will be added to the tests before the second infusion; a 24-hour urine collection only if bone density falls on treatment |
| Laboratory | Bone turnover markers (CTX or P1NP) | Baseline and 3 to 6 months after starting therapy | Not indicated | An infusion given in clinic makes adherence certain, and BHOF treats the markers as optional |
| Imaging | DXA of the hip and spine | Baseline after the fracture; every 1 to 3 years on therapy | Completed today | Left total hip T-score -2.8 (0.637 g/cm²); lumbar spine T-score -1.9 |
| Imaging | Vertebral fracture assessment | At baseline after a low-trauma fracture or with a T-score of -2.5 or lower | Deferred | Not done with today's DXA although both triggers apply, a deviation from the protocol. Treatment is already indicated by the hip fracture, so the decision is unchanged; he has no back pain and no height loss. Add it to the next DXA, sooner if back pain or height loss appears |
| Survey | FRAX 10-year fracture risk | After the fracture and with each DXA | Deferred | Not calculated with today's DXA, a deviation from the protocol. The hip fracture already establishes the need for treatment, so the decision is unaffected; calculate it with the next DXA |
| Medication safety | Antiresorptive therapy after the fracture | Promptly, within months of the fracture | Completed today | Zoledronic acid 5 mg given today, three months after the repair, once vitamin D was repleted |
| Examination | Standing height | Yearly | Completed today | 185 cm, unchanged |
| Examination | Pain assessment | Every visit | Completed today | No hip pain; scheduled acetaminophen stopped |
| Examination | Physical and occupational therapy progress | Every visit | Completed today | Barthel Index 75, up from 55; walking goal met |
| Examination | CDC STEADI fall-risk screen: fall history, gait and balance, postural blood pressure | Every primary care visit after the fracture | Completed today | No falls; steadier with the walker; no fall in blood pressure on standing |
| Examination | Timed Up and Go | When home therapy ends, then yearly or with a change | Due | Planned when home therapy ends, by the six-month review |
| Examination | Hip radiographs | Only for pain, loss of function, or suspected nonunion | Not indicated | No pain and steady progress |
| Examination | Home safety evaluation | At diagnosis and each follow-up | Completed today | Changes from the home safety assessment still in place |
| Medication safety | AGS Beers Criteria medication review | Every visit and at each transition of care | Completed today | Acetaminophen stopped; no Beers-listed medicine |
| Medication safety | Cholinesterase inhibitor benefit and tolerability | Each follow-up | Completed today | Heart rate 64; no fainting; continue |
| Survey | Neuropsychiatric symptom screen (NPI-Q) | Every visit | Completed today | Mild evening restlessness, unchanged; no hallucinations or aggression |
| Survey | Depression screen (GDS-15) | At 1, 3, and 6 months after the fracture; yearly in dementia | Completed today | Score 3, below the threshold of 5 |
| Survey | Cognitive test (MoCA), FAST stage, and ADL and IADL scores | At diagnosis, then yearly | Up to date | Done at the first visit and confirmed by neurology; next in about ten months |
| Survey | Caregiver assessment with the Zarit Burden Interview | At diagnosis, then every 6 to 12 months | Up to date | Repeat at the six-month review |
| Self-management | Advance care planning | At diagnosis, yearly, and at stage changes | Completed today | POLST form completed |
| Self-management | Calcium intake from food and supplements | Ongoing; target 1,000 to 1,200 mg a day | Completed today | Calcium-rich food at each meal; no calcium tablet needed |

## Goal progress

- Walk household distances with a walker and supervision, with a Barthel Index of 75 or more, by the three-month visit. Outcome by 2026-04-14: Barthel Index rose from 55 to 75; walks in the house and garden with a walker. **S**
- 25-hydroxyvitamin D of 30 ng/mL or more by three months, then the first zoledronic acid infusion. Outcome by 2026-04-14: 25-hydroxyvitamin D 36 ng/mL; zoledronic acid given. **S**
- No further falls through the six-month visit. In progress; target 2026-07-14. **S**
- Lower the spouse's Zarit Burden Interview score by at least 10 points by six months. In progress; target 2026-07-14. **S**
- Document a health care agent, goals of care, and a POLST form by the three-month visit. Outcome by 2026-04-14: Health care agent confirmed and POLST completed with the patient and spouse. **S**

## Medication changes

- Stopped: Acetaminophen 500 mg oral tablet, two tablets (1,000 mg) by mouth three times daily **S**
- Started: Zoledronic acid 5 mg/100 mL intravenous infusion over at least 15 minutes, once yearly **S**

## Guideline basis

- Management of Hip Fractures in Older Adults Evidence-Based Clinical Practice Guideline (2021), American Academy of Orthopaedic Surgeons
- The clinician's guide to prevention and treatment of osteoporosis (2022), Bone Health and Osteoporosis Foundation (Osteoporosis International)
- American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023), American Geriatrics Society
- Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD) (2024), Alzheimer's Association
- CMID: Clinical Monitoring Intelligence Database, Alzheimer's disease, hip/pelvic fracture, and osteoporosis monographs (2026), Aether Forge

## Follow-up

- Six-month post-fracture, dementia, and caregiver review in three months, with calcium and hemoglobin. **S**
- Next scheduled visit 2026-07-14: six-month post-fracture, dementia, and caregiver review. **S**
